HSV Vaccine Development: Unique Questions and Confounders

To view some of the files in this section, you will require a version of Adobe Acrobat. This is free to download and is available on the Adobe Acrobat website.

To view the PowerPoint presentations you will require Microsoft PowerPoint. You can download the latest PowerPoint viewer free from the Microsoft website.

You are welcome to download, view and use many of the slides contained in these presentations, however the original presenter and IHMF^Ž must be suitably acknowledged for any use, for example in oral presentations or written material. Please also be aware that some slides contain graphs, illustrations or other content that may not be the copyright of the presenter or the IHMF^Ž and permission ot use such material will need to be obtained from the copyright owner prior to use. Some of the slide presentations from the 13th IHMF^Ž Annual Meeting are subject to 'restricted use' and the presentations to which this applies are labelled with the notice 'Restricted Use - please contact the presenter prior to any use of the content of this presentation'. These 'restricted use' presentations may only be viewed online or downloaded to view, and the original presenter must be contacted prior to any use.

If you are in any doubt about your use of this material, please contact the IHMF Secretariat.

HSV Vaccine Development: Unique Questions and Confounders

Lawrence R. Stanberry, MD, PhD
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA

The development of effective vaccines may be the best approach to controlling the ongoing epidemic of genital herpes. The task of making an effective vaccine has been made difficult by the unique pathogenesis of mucocutaneous herpes simplex virus infections; in the immunocompetent host hematogenous dissemination does not play a key role in the pathogenesis of infection, an important step in the natural history of many vaccine preventable infections. Likewise, the control of a virus capable of establishing a persistent infection is particularly problematic as most vaccines prevent disease rather than infection. Besides discussing the pathogenesis of mucocutaneous herpes simplex virus infections, this presentation will address 5 questions:

Do vaccines protect animals against genital HSV-2 infection or disease?
Can a vaccine protect humans against genital herpes infection or disease?
Is it possible to induce a sterilizing mucosal immunity?
If a vaccine can protect against genital HSV-2 disease but not mucosal infection, does it impact latent and recurrent infections?
What are the immune correlates of protection against HSV-2 infection?

View

Download

The IHMFŽ is a registered trademark of PAREXEL MMS

Last Updated : 03/12/2007 18:16:28